The current COVID crisis has seen an unprecedented push by governments and pharmaceutical firms to wave normal regulatory protocols and licensing of vaccine products under the increasingly dubious guise of “Emergency Use Authorization.” Recently, concerned scientists have sought to audit the ongoing pharmaceutical clinical trials by exploring the issue of the informed consent. Research concludes that the forms provided to participants in corporate pharmaceutical trials for the current range of experimental COVID vaccines are woefully inadequate and clearly obfuscating health risks to those involved.
21st Century Wire –
According to a recent study conducted by Timothy Cardozo and Ronald Veazey entitled, “Informed consent disclosure to vaccine trial subjects of risk of COVID‐19 vaccines worsening clinical disease,” data reporting reveals that no sufficient literature exists “to require clinicians to disclose the specific risk that COVID-19 vaccines could worsen disease upon exposure to challenge or circulating virus.”
The authors proceed to note how the clear and present risks of participating in these large-scale experiment trials do indeed carry serious risks to participants, but that, “This risk is sufficiently obscured in clinical trial protocols and consent forms for ongoing COVID-19 vaccine trials that adequate patient comprehension of this risk is unlikely to occur, obviating truly informed consent by subjects in these trials.”
Conclusions drawn from the study and clinical implications are harrowing and should raise an ethical and humanitarian alarm regarding unabated government and pharmaceutical industry collusion, and cartel-like corruption being wrought on an unsuspecting and ill-informed public, on an unprecedented scale internationally, and which could result in a devastating implications to the health of countless recipients of experimental vaccine and mRNA gene therapy jabs.
The authors further note:
“……..that vaccines designed empirically using the traditional approach (consisting of the unmodified or minimally modified coronavirus viral spike to elicit neutralizing antibodies), be they composed of protein, viral vector, DNA or RNA and irrespective of delivery method, may worsen COVID-19 disease via antibody-dependent enhancement (ADE). This risk is sufficiently obscured in clinical trial protocols and consent forms for ongoing COVID-19 vaccine trials that adequate patient comprehension of this risk is unlikely to occur, obviating truly informed consent by subjects in these trials.”
“The specific and significant COVID-19 risk of ADE should have been and should be prominently and independently disclosed to research subjects currently in vaccine trials, as well as those being recruited for the trials and future patients after vaccine approval, in order to meet the medical ethics standard of patient comprehension for informed consent.